About S-adenosylmethionine decarboxylase proenzyme
S-adenosylmethionine decarboxylase proenzyme (AMD1) is a protein
from Homo sapiens identified by UniProt accession
P17707, 334 residues long.
MolForge cross-references it against 0 known binders and
38 disease associations.
Target properties
| Protein name | S-adenosylmethionine decarboxylase proenzyme |
|---|
| UniProt accession | P17707 |
|---|
| Gene | AMD1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 334 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (38)
Diseases linked to this target (Open Targets).
- neurofibrillary tangles measurement · score 0.25
- body height · score 0.18
- brain measurement · score 0.17
- sex hormone-binding globulin measurement · score 0.14
- self reported educational attainment · score 0.13
- neoplasm · score 0.05
- body fat percentage · score 0.05
- risk-taking behaviour · score 0.05
- mean corpuscular hemoglobin concentration · score 0.04
- breast cancer · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P17707-F1 | alphafold | PREDICTED | 93.38 | — |
Amino-acid sequence (334 residues)
MEAAHFFEGT EKLLEVWFSR QQPDANQGSG DLRTIPRSEW DILLKDVQCS IISVTKTDKQ EAYVLSESSM FVSKRRFILK TCGTTLLLKA LVPLLKLARD YSGFDSIQSF FYSRKNFMKP SHQGYPHRNF QEEIEFLNAI FPNGAAYCMG RMNSDCWYLY TLDFPESRVI SQPDQTLEIL MSELDPAVMD QFYMKDGVTA KDVTRESGIR DLIPGSVIDA TMFNPCGYSM NGMKSDGTYW TIHITPEPEF SYVSFETNLS QTSYDDLIRK VVEVFKPGKF VTTLFVNQSS KCRTVLASPQ KIEGFKRLDC QSAMFNDYNF VFTSFAKKQQ QQQS
Explore S-adenosylmethionine decarboxylase proenzyme with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets